News und Analysen

The prevailing mood lately on Wall Street has been positive. That has sent a lot of individual stocks higher over the past several weeks, particularly those with technology connections.

Shares of several health insurers were sinking on Wednesday. Centene (NYSE: CNC) stock was down 7.9% as of 12:13 p.m. ET, while CVS Health (NYSE: CVS) and Humana (NYSE: HUM) shares were falling 6.1%

MicroVision (NASDAQ: MVIS) shareholders continue to see elevated volatility in their portfolios. The computer vision tech specialist's shares were down by 23% as of 10:45 a.m. Wednesday, reversing

According to an old proverb, good things come to those who wait. That tends to be true in the stock market, at least for investors who buy shares of quality companies. Waiting, being patient, and

Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.

Biotech investors like it when one of their companies reports gains in a developmental program, and that was the dynamic behind Tuesday's rise in the share price of Aclaris Therapeutics (NASDAQ:

Shares of Surmodics (NASDAQ: SRDX) were up 16% early Tuesday afternoon as the healthcare company, which provides chemicals for in vitro diagnostic immunoassay tests and makes coatings for

Biotech growth stocks are inherently risky due to the plethora of competitive, financial, clinical, and regulatory hurdles unique to the industry. Despite these various risk factors, however, most

A Qatari billionaire has reportedly won the auction for English Premier League club Manchester United (NYSE: MANU). The club's common shares are soaring as a result, up 10% on Tuesday morning.

Nvidia's (NASDAQ: NVDA) first-quarter report is one of the most important things to happen in the stock market this year. Not only did the semiconductor specialist deliver Q1 sales and earnings that

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

Shares of Omeros (NASDAQ: OMER) were down 12.9% early Monday afternoon after the clinical-stage biopharmaceutical company released a presentation it made regarding a therapy to treat a rare blood

Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis. 

Chinook is a

The stock market has the potential to make just about anybody with enough patience and discipline a millionaire. This is because it has historically delivered 10% annual total returns over the long

These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions.

Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and

Sell in May and go away? The old adage hasn't proven to be great advice in 2023. The stock market has risen so far in June and could go even higher.

Three Motley Fool contributors think some stocks

Shares of AngioDynamics (NASDAQ: ANGO) were up more than 8% Friday afternoon after rising as much as 9.1% on the news the medical technology company had sold some of its assets for $100 million. The

Fool.com contributor and finance professor Parkev Tatevosian compares ZIM (NYSE: ZIM) and AT&T (NYSE: T), two of the cheapest stocks he follows.

*Stock prices used were the afternoon prices of June

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

Biotech company Novavax (NASDAQ: NVAX) has fallen from grace over the past year, with the vaccine maker's shares dropping by 84% over the trailing-12-month period. But Wall Street hasn't given up on